

The following manuscript was accepted for publication in Pharmaceutical Sciences. It is assigned to an issue after technical editing, formatting for publication and author proofing
Citation:

Parveen RS, Hedge S, Nayak V. Investigational drugs for the COVID 19 pandemic – a concise review, Pharm. Sci. 2020, doi: 10.34172/PS.2020.80

Investigational drugs for the COVID 19 pandemic – a concise review

Reena Sherin Parveen, Shreya Hegde, Veena Nayak*

Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal , Karnataka, -576104, India

Running title: Drugs for COVID 19

Corresponding author :

Dr Veena Nayak
Associate Professor
Department of Pharmacology,
Kasturba Medical College, Manipal,
Manipal Academy of Higher Education, Manipal,
Karnataka, -576104, India
Ph: 9844773573

Email:veena.nayak@manipal.edu

Abstract: The present year saw the emergence of a pandemic Corona Virus Disease of 2019 (COVID 19). The unpreparedness for the pandemic and lack of drugs/vaccine against this virus has led to a high mortality rate across the world. In the process, a number of drugs have been tried against the corona virus including antivirals like remdesivir, lopinavir-ritonavir, and favipiravir, monoclonal antibodies like tocilizumab and sarilumab and antimalarial drugs like chloroquine and hydroxychloroquine. At the present time, none of these drugs have reported efficacy against the virus. Here we present a review of all these drugs, their proposed mechanism of action against the corona virus and their status in clinical trials.

Keywords: Antivirals, antimalarial drug, monoclonal antibody, COVID 19

Introduction

Since 2002, the world has witnessed the occurrence of three coronaviruses namely, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East respiratory syndrome related Coronavirus (MERS-CoV) and the SARS-CoV-2, a new human pathogen being the causative agent of COVID-19. In December 2019, SARS-CoV-2 arose in Wuhan, China, and this novel coronavirus (2019-nCoV), was identified as the causative agent.¹ Ever since this virus has had a significant impact on health, morbidity and mortality rates, health services and economy of the people all over the globe .

The disease spectrum of COVID-19, varies in severity, ranging from asymptomatic carrier state to mild respiratory tract infection to fatal pneumonia. Furthermore, SARS-CoV-2 can spread within the family, community and hospitals, and has turned into a public health emergency of international concern (PHEIC), declared by the World Health Organization(WHO) on 30 January 2020.² Confirmed cases of COVID-19 have been reported in 56 countries and territories with the global number of confirmed cases being 2,83,31,121, including 9,13,015 deaths as of August 25, 2020, according to the WHO.³

Drug targets on the novel corona virus (CoV): The seven major targets are (spike protein (S), envelop protein (E), membrane protein (M), protease, nucleocapsid protein (N), hemagglutinin esterase (HE), and helicase against which drugs are being designed. There are sixteen nonstructural proteins (NSPs) that are required for the formation of replicase transcriptase complex which are also being considered as drug targets.

CoV mechanism of infection : CoV attaches to the target cells with the help of the spike protein (S) . The receptor for it is the angiotensin-converting enzyme 2 (ACE2) on the host cell. The enveloped virus can enter directly or via internalisation by endocytosis. Then the genome of the virus is released into the cytoplasm of the host cell by various lysosomal enzymes. The viral genome enters the ribosomes and endosomes. ORF1a and ORF 1b genes

produce polypeptides which take command over host ribosomes and synthesizes 16 NSPs which have an important role in replication and transcription. Once the structural proteins and mature virions are formed, they are then released from the infected cell through exocytosis.⁴ There have been no drugs, vaccines or monoclonal antibodies which have been approved for the treatment of human infections due to coronaviruses. Here we present a review of drugs which have been used to date against this pandemic and we have included all experimental medications for COVID19 that are stated in WHO, Infectious diseases society of America (IDSA), National Institutes of Health (NIH) and National Institute for Health and Care Excellence (NICE) guidelines.

Hydroxychloroquine

Hydroxychloroquine(HCQ) is an aminoquinoline which is less toxic and more soluble than chloroquine.

HCQ raises the endosomal pH and hinders the glycosylation of the cellular receptor of SARS-CoV and thus blocks viral infection. It also exerts its antiviral effect via a modulating effect on the activated immune cells. It also has an additional action through downregulation of the expression of Toll-like receptors (TLRs) and reduction in interleukin-6 production.⁵ The risk of retinal toxicity is less with HCQ when compared to chloroquine due to decreased permeability to the blood-retinal barrier and rapid clearance from the pigment cells of the retina as it has an additional hydroxyl group.⁶

In a study conducted by Gautret et al. in Marseille, France, it was shown that HCQ by itself, and also the combination of HCQ along with azithromycin, when administered for three to six days, was greatly effective in the clearance of nasopharyngeal carriage of the virus in test subjects affected with COVID-19 when compared to control.⁷

In an observational study conducted at a large medical centre in New York City involving hospital-admitted COVID-19 patients, the outcomes were compared among those who received HCQ with those who did not, and it was found that there was no significant association between HCQ use and the composite end point of intubation or death.⁸

A comparative retrospective cohort study evaluating the clinical outcomes of COVID-19 patients hospitalized at the Henry Ford Health System (HFHS) in Southeast Michigan demonstrated that in a strictly monitored protocol-driven in-hospital setting, treatment with HCQ alone and HCQ + azithromycin was associated with a significant reduction in mortality among patients hospitalized with COVID-19.⁹

A case-control study was conducted in India to identify the factors associated with SARS-CoV-2 infection among health care professionals in the country. The study reported that the consumption of four or more maintenance doses of HCQ was associated with a significant decline in the risk of SARS-CoV-2 infection among the study participants. It is stressed that the protective effects of the drug are seen with the intake of four or more maintenance doses of HCQ. The National Task Force for COVID-19 in India recommended once a week maintenance dose for seven weeks (400 mg once weekly), following the loading dose (400 mg twice a day). The multivariate model in the study indicates HCQ prophylaxis should be taken in tandem with personal protective equipment (PPE) use.¹⁰

A randomized, double-blind, placebo-controlled trial was conducted across the United States and certain parts of Canada to test HCQ as a post-exposure prophylaxis for COVID-19. Adults who had either high-risk to moderate-risk of occupational or household exposure to individuals with confirmed COVID-19 were enrolled in the study. The study results revealed that HCQ when used as post-exposure prophylaxis (administered within 4 days of exposure) did not prevent illness compatible with Covid-19 or confirmed infection.¹¹

Food and Drug Administration (FDA) reviewed the safety issues of HCQ and chloroquine to treat hospitalized COVID-19 patients for events of serious heart rhythm problems and other safety issues including blood and lymph system disorders, kidney and liver injuries. Based on this report, FDA cautioned against the administration of HCQ and chloroquine for COVID 19 patients outside the hospital setting or clinical trial due to the risk of heart rhythm problems on July 1, 2020.¹²

The Indian Council of Medical Research (ICMR), has recommended chemoprophylaxis with HCQ for all asymptomatic healthcare workers involved in containment and treatment of COVID-19, and asymptomatic healthcare workers employed in non-COVID hospitals/non-COVID areas of COVID hospitals/blocks, asymptomatic frontline workers, such as surveillance workers deployed in containment zones and paramilitary/police personnel involved in COVID-19 related activities and for asymptomatic household contacts of confirmed cases. Electrocardiography (ECG) should be monitored before the prophylactic regimen and during the prophylaxis and the drug should be given under medical supervision with administration of informed consent. HCQ would be taken 400mg twice a day on Day1 and 400mg once weekly for the next 3 weeks for household contacts and 7 weeks for asymptomatic healthcare workers and front line workers. This was revised on 23rd May 2020 to expand its indication.

The experts further recommended for its use beyond 8 weeks on weekly dosage with strict monitoring of clinical and ECG parameters which would also ensure that the therapy is given under supervision.¹³

Remdesivir

It (GS-5734) is an antiviral drug with a broad spectrum of activity, produced by Gilead Science Inc. in the year 2017 as a treatment option for Ebola virus contagion. This is an experimental drug that has not yet received approval by the FDA.

Remdesivir is a nucleotide analogue prodrug that inhibits RNA-dependent RNA polymerase(RdRp). It metabolizes into its active form which exerts its action by escaping proofreading by the viral exonuclease thus leading to a reduction in the production of RNA.¹⁴

A randomized double-blind clinical trial including 308 hospitalized patients diagnosed with mild or moderate COVID-19 were administered parenteral remdesivir as 200mg loading dose on the first day followed by 100mg intravenous once daily for a period of 9 days. The study aimed to assess the safety and efficacy of the drug.¹⁵ Another phase 3 placebo-controlled clinical trial is being done in 452 hospitalized adult patients to evaluate the efficacy and safety of parenteral remdesivir in severe respiratory infection due to COVID-19.¹⁶

Compassionate treatment with parenteral remdesivir was provided to the first case of COVID-19 in Washington, USA, on the seventh day of hospitalisation for the progression of pneumonia. The patient's condition remarkably improved with no evident adverse effects.¹⁷

In a cohort study conducted on hospitalized severe COVID patients, remdesivir showed clinical improvement in 36 of 53 patients.¹⁸

The Drug Controller General of India (DCGI) approved remdesivir lyophilised powder for emergency use in patients hospitalised with severe COVID-19.

ICMR, has been considering the use of remdesivir, an antiviral drug that has shown improvement in COVID-19 patients in formal clinical trials. Currently, remdesivir is allowed for emergency/compassionate use in treating severely-ill Covid-19 patients and it is likely to be part of the revised protocol.¹⁹

Favipiravir

It is an antiviral agent that selectively and potently inhibits viral RNA-dependent RNA polymerase (RdRp).²⁰ The drug is active against a broad range of RNA viruses.

It was approved for the treatment for novel or re-emerging influenza viruses in 2014 in Japan.²¹

Favipiravir is a prodrug that undergoes intracellular phosphoribosylation by certain cellular enzymes like hypoxanthine-guanine phosphoribosyltransferase(HGPRT) to an active form, favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate).²² Favipiravir-RTP is recognized as a substrate by RdRp of the RNA virus. On being incorporated to the viral RNA, it acts as a chain terminator and prevents RNA elongation.²³

A highly conserved lysine residue of RdRp plays a key role in the broad spectrum antiviral activity of favipiravir against positive-sense single-stranded RNA viruses.²⁴

Several trials to assess the safety and efficacy of favipiravir as a single agent and also in combination with protease inhibitors in COVID-19 patients are in progress. In March 2020, favipiravir was claimed by the National Medical Products Administration of China to have demonstrated efficacy with minimal side effect.²⁵

An open-labeled comparative controlled study was conducted in Shenzhen, China which showed faster viral clearance and better chest imaging changes in comparison with lopinavir/ritonavir in COVID-19 patients. The dose given in this study was 1600 mg twice daily on Day 1 and 600 mg twice daily orally on Days 2–14.²⁶

An open-label, randomized, multi-center clinical trial was conducted by Glenmark pharmaceuticals to compare the safety and efficacy of favipiravir plus standard supportive care and standard supportive care alone in mild-moderate COVID-19 patients. A faster viral clearance and improvement in clinical symptoms were seen with favipiravir-treated group.²⁷

The FDA has granted clearance to Appili Therapeutics to expand its phase II study to assess the safety and efficacy of favipiravir in controlling outbreaks following exposure to COVID-19 in long-term care (LTC) facilities. This study intends to explore the prophylactic potential of favipiravir.²⁸

The adverse effects reported for favipiravir include an increase in uric acid levels, mild diarrhoea, elevated transaminases and reduced neutrophil count.²⁹

Lopinavir-ritonavir

Lopinavir is a human immunodeficiency virus (HIV) type 1 aspartate protease inhibitor. It also has an *in vitro* inhibitory activity against SARS-CoV, the virus causing SARS in humans.³⁰

Ritonavir is combined with lopinavir to increase its plasma half-life by the inhibition of cytochrome P450.

Lopinavir/Ritonavir inhibit HIV type 1 aspartate protease enzyme. This enzyme is involved in the production of structural proteins and enzymes of the virus from the large viral polyprotein synthesized inside the infected cell. The drug binds to the active site of aspartate protease enzyme thereby preventing the formation of functional viral proteins.³¹ SARS-CoV-2 is a single-stranded RNA beta-coronavirus. The processing of viral RNA inside the host cell is carried out by the enzyme, 3-chymotrypsin-like protease (3CL^{pro}). Though the binding site in the corona virus protease structurally varies from the HIV protease, *in vitro* studies have shown lopinavir exhibiting antiviral activity against SARS-CoV-2.³²

Several trials are being conducted to test the efficacy of lopinavir/ritonavir in patients of COVID-19. In a study conducted in hospitalized adult patients with severe COVID-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care in terms of time to clinical improvement and mortality.³³

The commonly tried dosage regimens in the ongoing trials are 400 mg/100mg or 200 mg/ 50 mg of oral lopinavir/ ritonavir, given twice daily orally for 14 days. It is contraindicated in porphyria and should be cautiously used in patients with haemophilia, pancreatitis and cardiac conduction disorders.

A randomized, controlled, open-label trial involving hospitalized adult patients with severe COVID-19 was conducted in China. The patients were assigned in a 1:1 ratio to receive either lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to

standard care, or standard care alone. The study failed to show any improvement with lopinavir-ritonavir beyond standard care.³⁴

One of the largest clinical trials conducted on the potential COVID-19 treatment options, the RECOVERY Trial (Randomised Evaluation of COVID-19 therapy) concluded that lopinavir-ritonavir failed to provide any mortality benefit over standard care. Hence randomization was discontinued to lopinavir-ritonavir treatment arm.³⁵

The Solidarity clinical trial was launched by the WHO and other partners in the wake of COVID-19 to find an effective treatment for the disease. The International Steering committee analyzed the data from the interim trial results and concluded that lopinavir-ritonavir showed little or no benefit when compared to standard of care in hospitalized COVID-19 patients. This led to the discontinuation of patient recruitment to the lopinavir-ritonavir treatment arm in the above trial.³⁶

The adverse effects reported for lopinavir/ritonavir include gastrointestinal disturbances diarrhoea, abdominal pain, nausea, dyslipidaemia, diabetes mellitus and pancreatitis.³⁷

Tocilizumab

It is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R).³⁸ It is approved for use in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arthritis and cytokine release syndrome.³⁹

Patients of COVID-19 are found to have increased plasma concentrations of inflammatory cytokines like tumor necrosis factor alpha(TNF α), interleukin 2,7 and 10, granulocyte -colony stimulating factor(G-CSF) and monocytes chemoattractant protein 1 alpha indicating a cytokine storm. It is believed that the pathogenic T cells and inflammatory monocytes with high IL-6 secretion may enter the pulmonary circulation and incite an inflammatory storm in

severe/ critical COVID-19 patients.⁴⁰ Tocilizumab, by blocking the IL-6 receptors prevents the IL-6 signal transduction to inflammatory mediators and thus calms the cytokine storm.⁴¹

Treatment with tocilizumab was included in the diagnosis and treatment program of COVID-19 (7th trial version, released on 3rd March 2020) by the National Health Commission of China. It is advised for use only in patients with extensive bilateral lung lesions opacity or critical patients with elevated laboratory detected IL-6 levels.

Further large scale, multicentre clinical trials are underway to get clear evidence on the safety and efficacy of the drug. (ClinicalTrials.gov Identifier: NCT04317092, NCT04335071, NCT04310228). Tocilizumab is administered through intravenous infusion wherein the first dose to be given is 4-8 mg/kg, diluted in 100 ml with 0.9% normal saline, the infusion time not less than 60 minutes. If required a repeat administration of the above dose may be done after 12 hours. A single dose should not exceed 800mg and not more than two doses should be administered.⁴² An observational, retrospective cohort study conducted on adults with severe COVID-19 pneumonia in tertiary health centres of Italy concluded that both intravenous and subcutaneous tocilizumab administration is likely to reduce the risk of invasive mechanical ventilation or death.⁴³ In another retrospective cohort study on a small group of hypoxic COVID-19 patients, tocilizumab was associated with a significantly shorter duration of vasopressor support.⁴⁴

Both the above mentioned studies stressed the need for further clinical trials to validate their findings.

The CHIC study, prospectively investigated whether an intensive course of glucocorticoids with or without tocilizumab for patients with severe COVID-19 associated with cytokine storm syndrome showed faster clinical improvement, decreased mortality and reduced likelihood of mechanical ventilation. The study involved a comparison of these patients with a historic cohort of age- and sex-matched COVID-19 patients with cytokine storm syndrome who were

given standard supportive care. The patients on glucocorticoids with or without tocilizumab were found to be more likely to attain the primary and secondary outcomes than the controls.⁴⁵ Roche announced the results of its phase III COVACTA trial which was a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of intravenous tocilizumab added to standard of care in hospitalised adult patients with severe COVID-19 associated with pneumonia compared to placebo plus standard of care. The primary and secondary endpoints included assessment of clinical status, mortality, need for mechanical ventilation and intensive care unit (ICU) variables at the end of four weeks. The study failed to meet the primary and key secondary endpoints.⁴⁶ Several phase II and III studies with tocilizumab (MARIPOSA, REMDACTA and EMPACTA trials) are underway.

The adverse effects reported with tocilizumab include injection site reactions, upper respiratory tract infections, headache and diarrhoea.⁴² It is contraindicated in patients with known hypersensitivity to tocilizumab or its excipients, diagnosed with tuberculosis and other active infections.

Sarilumab:

It is a human monoclonal antibody against IL-6 signalling originally approved for the treatment of moderate rheumatoid arthritis.

IL-6 is also responsible for life-threatening inflammatory response that causes acute respiratory distress syndrome (ARDS) in patients who are critically ill due to COVID-19.⁴⁷ It is a pleiotropic cytokine produced by different cell types like macrophages, fibroblasts, etc. during sepsis and organ injuries. IL-6 induces acute phase response leading to leucocyte recruitment and infiltration and it is a poor prognostic marker in patients with acute lung injury.⁴⁸

In multisite clinical trials enrolling COVID -19 patients, sarilumab was administered intravenously in different doses. In a preliminary case series from China, Sarilumab has reduced the requirement of supplemental oxygen in 15 patients and reduced temperature out of

the 20 patients. China has updated its guidelines and added sarilumab for the treatment of critical patients with COVID 19.⁴⁷ The safety and efficacy details of this drug is not yet available. The adverse effects reported when used for rheumatoid arthritis were mild upper respiratory tract infections, injection site reactions, neutropenia and elevated liver enzymes.⁴⁹

Arbidol Hydrochloride (Umifenovir)

Arbidol acts as an entry inhibitor against influenza viruses as well as arboviruses which has been approved in Russia and China.⁵⁰

The main target of arbidol is hemagglutinin (HA) which is the major glycoprotein present on the surface of the influenza virus. After endocytosis, the drug inhibits the fusion of the influenza viral membrane with the endosome.⁵⁰

Arbidol was compared with favipiravir in a randomized clinical trial and the latter was shown to be superior in treatment outcome in 240 COVID-19 positive patients.⁵¹ A recent meta-analysis concluded that umifenovir is safe, however the data on efficacy in COVID -19 is limited. The meta-analysis concluded that umifenovir could not improve patient- important outcomes in COVID- 19.⁵²

Anakinra

Anakinra is a recombinant human Interleukin (IL)-1 receptor antagonist usually employed for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes.⁵³

The mechanism of action is by inhibition of IL-1 α and IL-1 β which are the pro-inflammatory cytokines.⁵⁴

In a case-series report in which anakinra was used in nine patients with moderate to severe COVID-19 pneumonia, the drug was well tolerated. Anakinra improved C reactive protein (CRP) by day 11 and resolved the changes in computerised tomography (CT) scan of chest as

well. All the nine patients with COVID 19 survived with anakinra. ⁵⁵ There was a significant improvement in pulmonary function and it also minimized the need for use of vasopressors. In a retrospective cohort study conducted by Cavalli g. et al. in Italy on 29 COVID-19 patients with moderate-to-severe ARDS, along with hyper inflammation, it was shown that additional treatment with parenteral anakinra was safe and it reduced serum levels of CRP and progressively improved the respiratory function in 72% of the patients.⁵⁶

In a meta-analysis review done by Hong D. et al. for assessment of the safety and efficacy of anakinra, it was observed that the drug was well tolerated and the main adverse event among patients who were treated with anakinra was skin rash.⁵⁷

Baricitinib - Janus Kinase Inhibitor

These agents inhibit the Janus kinase (JAK)-signal transducer and activator of transcription (JAK-STAT) pathway and are assumed to be useful in the management and treatment of severely ill patients infected with COVID-19.⁵⁸

Majority of the viruses enter the cells through a process of endocytosis which is receptor-mediated. Disrupting one of the regulators of endocytosis, the AP2-associated protein kinase 1 (AAK1) by the JAK inhibitor can interrupt the virus entry into cells and also interfere with the assembly of virus particles intracellularly.⁵⁹ Baricitinib is a JAK1 and JAK2 inhibitor that is shown to possess a dual effect including viral entry reduction and decline in viral inflammation in COVID-19 patients via AAK1 inhibition.

Due to its high affinity and relative safety profile baricitinib was suggested as a potential candidate in the management of patients with COVID-19. When administered as a once-daily dose of 2 mg or 4 mg, sufficient plasma concentration could be attained for inhibition.⁶⁰ It has low plasma protein binding and minimal enzyme interaction which makes it appropriate to be included in combination therapies with directly acting antiviral agents like remdesivir and others.⁶¹

In an open-label study including 12 patients diagnosed with moderate COVID-19 pneumonia in Italy, a combination therapy of baricitinib with lopinavir/ritonavir administered in such patients showed a noteworthy clinical improvement along with laboratory parameters.⁶² Among these patients, none of them needed an ICU support.

The use of baricitinib has shown an increase in thromboembolic events including deep vein thrombosis and pulmonary embolism which is important, as the COVID-19 patients have a possibility of developing such events.⁶³

Other adverse effects such as anaemia, increase in creatine kinase levels have been associated with baricitinib therapy. Risk of re-activation of latent infections such as tuberculosis and hepatitis B is also seen in infected patients.⁶⁴

Corticosteroids

Corticosteroids could play a role in the advanced disease stage by suppression of lung inflammation owing to their potent action as an anti-inflammatory agent and antifibrotic properties.⁶⁵

Corticosteroids in low doses downregulate the transcription of pro-inflammatory cytokines, thereby preventing a prolonged cytokine response. Corticosteroids also hasten the resolution of pulmonary and systemic inflammation in COVID-19 patients with pneumonia.⁶⁶ They may also aid improvement in the immune response that has been dysregulated due to the associated complication such as sepsis.⁶⁷ Corticosteroids can raise the blood pressure in patients with hypotension.⁶⁸

In the RECOVERY trial, low-dose dexamethasone administered for 10 days was shown to decrease mortality among severe COVID-19 patients with respiratory complications.⁶⁹ Presently, systemic corticosteroids are not recommended for routine use in the management of viral pneumonia by the WHO, unless they are specified for another purpose, such as exacerbation of chronic obstructive pulmonary disease or bronchial asthma or patients with

refractory septic shock.⁷⁰ In a study done by Wang et al., 46 patients diagnosed with severe COVID-19 pneumonia with acute respiratory failure, who were treated with intravenous methylprednisolone showed improvement in clinical parameters in 26 of them.⁷¹ A study done by Wu et al. demonstrated that methylprednisolone treatment in ARDS patients with coronavirus infection reduced the death rate.⁷² Higher dose methylprednisolone for the management of cytokine storm is recommended as follows: 60–125 mg every 6 hours for a maximum of 3 days, and dose tapering following this based on CRP levels.⁷³

Some studies like Wang et al. have reported ineffective outcomes in COVID-19 patients treated with glucocorticoids, indicating that the benefit of corticosteroid use is outweighed by its adverse effects.⁷⁴ Due to lack of evidence corticosteroid use has not been supported by the WHO, as mentioned in their interim guidelines for the management of viral pneumonia and ARDS in suspected COVID-19 patients.⁷⁵

The use of glucocorticoids may inhibit immune response, reduce pathogen clearance and increase the chances of viral replication in COVID-19 patients. In a study done by Russell et al., clinical evidence was not sufficient to support corticosteroid use for the management of COVID-19 patients with lung injury.⁷⁶

Azithromycin

Azithromycin is a macrolide antibiotic whose immunomodulatory and antiviral properties a role in the treatment of patients with COVID-19.⁷⁷

The immunomodulatory action of azithromycin is exerted on the intracellularly located mitogen-activated protein kinase (MAPK) and inhibition of the nuclear factor-kappa B (NF- κ B) pathway along with its effect on extracellular signal-regulated kinases 1/2 (ERK1/2). This mechanism influences cellular functions such as cell proliferation and inflammatory cytokine production thus aiding in controlling the cytokine storm occurring in COVID-19 patients.⁷⁸

The *in vitro* antiviral activity of azithromycin in the early phase of infection included blocking

the internalization into the host cells and inactivation of the viral endocytic activity which contributed towards decreasing viral replication.⁷⁹ It is shown that azithromycin has anti-inflammatory effects in both acute and resolution phases of the viral infection. It decreases the production of pro-inflammatory cytokines including IL-8, IL-6, TNF alpha, and MMPs in the acute phase and increases the inflammation-related oxidative stress and neutrophil apoptosis in the resolution phase.⁸⁰

Not much data is available to suggest the positive effect of azithromycin when administered along with chloroquine or HCQ in the management of ARDS patients affected with SARS-CoV-2 infection.

In a retrospective study conducted by Rosenberg et al. on 1438 hospitalized COVID-19 patients, 735 patients were treated with a combination of HCQ and azithromycin and no significant differences were seen in the in-hospital mortality among those who were treated with the combination compared to the patients who received monotherapy with either drug.⁸¹

A non-randomized open-label clinical trial done in China on SARS-CoV-2 infected patients demonstrated a synergistic effect of HCQ and azithromycin combination therapy via a reduction in the levels of SARS-CoV-2 RNA in the upper respiratory tract specimens, without any comments regarding clinical benefits of such treatment.⁸² Another observational study conducted on SARS-CoV-2 hospitalized patients in China, treated with the combination of HCQ and azithromycin neither showed evidence of any clinical benefit nor demonstrated rapid clearance of viral RNA.⁸³

Both HCQ and azithromycin can cause corrected QT (QTc) prolongation, further leading to fatal arrhythmias. Caution should be exercised in such patients and also those with hepatic or renal dysfunction.⁸⁴

Ivermectin

Ivermectin is a broad spectrum FDA approved anti-parasitic and antiviral drug which has shown its efficacy in the treatment of COVID-19 as a second line drug. An *in vitro* study conducted to demonstrate ivermectin effect on SARS-CoV-2 showed inhibition of viral replication.⁸⁵

The mechanism of ivermectin against SARS-CoV-2 is not clearly known and probably could be similar to the mechanism by which it exerts antiviral activity against other viruses. The viral integrase protein and importin (IMP) $\alpha/\beta 1$ heterodimer are known to increase viral infection by nuclear import process which is inhibited by ivermectin.^{85,86}

Ivermectin when administered at lower doses were shown to decrease the viral load thus providing an advantage to the immune system through developing an antiviral response against infection caused by SARS-CoV-2.⁸⁷ However, a pharmacokinetic simulation process studied by Schmith et al. showed that the inhibitory concentration of ivermectin needed for an effective antiviral activity against SARS-CoV-2 was higher than the maximum concentration attained in the plasma by the approved dose. Thus ivermectin seems to have partial benefit in the management of COVID-19.⁸⁸

Further clinical trials are needed to establish the safety and efficacy in COVID-19 infected patients.

The main drawback of ivermectin is its cytotoxic potential that limits the clinical utility. Modification of the pharmacokinetic properties by alteration of the vehicles utilized in the formulations can significantly improve the systemic concentration of this drug.⁸⁹

Vitamin C

The antimicrobial and immunomodulatory properties of the micronutrient and dietary supplement vitamin C are well recognized to reduce the possibility of infections, mostly in high concentrations.⁹⁰

Vitamin C inhibits activation of the pro-inflammatory transcription factor, nuclear factor kappa-B (NFκB) which provides immune support through the genetic regulation of various inflammatory mediators.⁹¹ In the host defence cells, vitamin C regulates the redox-signal transduction of cytokines and probably controls inflammatory responses by inhibiting the granulocyte macrophage colony stimulating factor (GM-CSF) signalling pathway.⁹² A study conducted by Chen et al. showed that vitamin C inhibits oxidative stress further halting the cytokine storm progression thereby improving immunity in the host.⁹³ Vitamin C also has a positive effect in the bronchial epithelium of humans by the process of oxidative damage repair through modulation of both inflammatory expression and generation of reactive oxygen species (ROS).⁹⁴ Vitamin C has demonstrated antiviral activity *in vitro* through inhibition of the process of replication in different viruses including influenza A virus.⁹⁵

In a randomized controlled trial conducted on 167 patients diagnosed with sepsis-related ARDS, approximately 15 g/day of intravenous vitamin C was administered for a period of 4 days which may have been a reason for decreased mortality in such patients.⁹⁶ In another study conducted in China on 50 patients with moderate to severe COVID-19, an improvement in the oxygenation index was seen following the administration of high-dose intravenous vitamin C with complete recovery.⁹⁷ Further, patients are being recruited for prospective randomized controlled trials in which high dose intravenous vitamin C will be administered for the management of COVID-19, expecting an improvement in the pulmonary function in such patients along with a reduction in mortality.⁹⁸ Due to insufficient evidence against COVID-19 virus, the recommendations for the intake of vitamin C are limited.

Vitamin D

The micronutrient vitamin D has shown to interfere with viral replication exhibiting antiviral activity along with immunomodulatory action and anti-inflammatory property.⁹⁹

Vitamin D reduces the pro-inflammatory cytokine concentration, enhances anti-inflammatory cytokine concentration, improves cellular innate immunity and decreases the rate of viral replication by inducing antimicrobial peptides such as cathelicidins and defensins. These peptides disturb the invading pathogen cell membranes and also counteract the endotoxin activity thereby reducing lung inflammation and the occurrence of pneumonia.¹⁰⁰ Vitamin D can also decrease the production of pro-inflammatory Th1 cytokines including TNF α and interferon γ (IFN γ).¹⁰¹ Macrophages have shown to diminish the pro-inflammatory cytokine expression and raise the anti-inflammatory cytokine expression on administration of micronutrient vitamin D thus decreasing the risk of infection.¹⁰²

A reduction in hospital-related infections was observed when vitamin D supplements were administered in such patients in order to increase the serum 25-hydroxy vitamin D (25(OH)D) concentration.¹⁰³ A recent review has proposed that the risk and severity of infection with COVID-19 can be decreased by administering 50,000-IU capsules of vitamin D in loading doses of 200,000–300,000 IU.¹⁰⁴ An observational study which explored the association between serum concentrations of 25(OH)D and the risk of developing acute respiratory tract infections (ARTIs) in healthy adults, showed that 25(OH)D concentrations of 38 ng/mL or more were significantly associated with a twofold reduction in ARTIs along with a striking decrease in the percentage of days ill.¹⁰⁵ Also, a study done on SARS-CoV-2 positive patients in Switzerland demonstrated a significant reduction in 25(OH)D levels.¹⁰⁶ Thus, the hypothesis that vitamin D micronutrient supplementation can lead to decreased incidence in COVID-19 needs to be probed in clinical trials in order to regulate the dose of drug administered in accordance with serum 25(OH)D concentrations along with safety concerns.

Zinc

Zinc supplementation is hypothesized to play a role in the prophylaxis and treatment of COVID-19.¹⁰⁷

Zinc is known to enhance the antiviral immune response through various mechanisms as demonstrated by certain *in-vitro* and *ex-vivo* studies.^{108,109} In an *in-vitro* study conducted by te Velthuis et al. it was demonstrated that zinc exhibited direct inhibitory action on RNA-dependent RNA-polymerase activity which implied direct inhibition of SARS-CoV-2 replication.¹⁰⁹ Zinc plays an important role in cell-mediated immunity, regulates the function and proliferation of neutrophils, macrophages, natural killer cells and lymphocytes and controls the production of cytokines by the immune cells. Zinc has also shown to provide protection against ROS effects that are produced during the inflammatory processes.¹¹⁰

Several studies on COVID-19 patients are being conducted to assess if zinc administration along with standard antiviral therapy is associated with favourable clinical outcomes. (ClinicalTrials.gov Identifier: NCT04370782, NCT04335084, NCT04342728, NCT04446104).

The recommended daily allowance for healthy adults is usually around 15–30 mg of elemental zinc and long-term high-dose zinc can lead to adverse effects such as decreased levels of high-density lipoprotein cholesterol, copper deficiency and anaemia.¹¹¹

Drug	Mechanism of action
Hydroxychloroquine	<ul style="list-style-type: none">• raises the endosomal pH, prevents endocytosis; inhibits glycosylation of cellular receptor of SARS-CoV (ACE2), thereby preventing viral entry• downregulation of the expression of Toll-like receptors (TLRs) and reduction in IL-6 production
Remdesivir	<ul style="list-style-type: none">• inhibits RNA-dependent RNA polymerase and prevents viral replication and nascent viral synthesis

Favipiravir	<ul style="list-style-type: none"> Favipiravir-RTP (favipiravir ribofuranosyl-5'-triphosphate), a substrate by RdRp of the RNA virus, gets incorporated to the viral RNA and acts as a chain terminator and prevents RNA elongation
Lopinavir-ritonavir	<ul style="list-style-type: none"> binds to the active site of aspartate protease enzyme thereby prevents the formation of functional viral proteins
Tocilizumab	<ul style="list-style-type: none"> blocks the IL-6 receptors, prevents the IL-6 signal transduction to inflammatory mediators and calms the cytokine storm
Sarilumab	<ul style="list-style-type: none"> human monoclonal antibody against IL-6 which is responsible for inducing the acute phase response by recruiting leucocytes
Arbidol	<ul style="list-style-type: none"> binds to the hemagglutinin (HA) on the surface of the virus and inhibits the fusion of the influenza viral membrane with the endosome.
Anakinra	<ul style="list-style-type: none"> recombinant human IL-1 receptor antagonist which inhibits the actions of IL-1α and IL-1β which are the pro-inflammatory cytokines
Baricitinib	<ul style="list-style-type: none"> A Janus kinase inhibitor, disrupts the regulators of endocytosis, the AP2-associated protein kinase 1 (AAK1) and prevents viral entry

Corticosteroids	<ul style="list-style-type: none"> • downregulate the transcription of pro-inflammatory cytokines, thereby preventing a prolonged cytokine response
Azithromycin	<ul style="list-style-type: none"> • influences cellular functions such as cell proliferation and inflammatory cytokine production by influencing MAPK, NF-κB, ERK1/2.
Ivermectin	<ul style="list-style-type: none"> • Inhibits the viral integrase protein and importin (IMP) α/β1 heterodimer which increase viral infection
Vitamin C	<ul style="list-style-type: none"> • inhibits pro-inflammatory transcription factors, NFκB • regulates the redox-signal transduction of cytokines • controls inflammatory responses by inhibiting the GM-CSF signalling pathway • inhibits oxidative stress further stopping the progression to cytokine storm
Vitamin D	<ul style="list-style-type: none"> • reduces the pro-inflammatory cytokine including TNFα and IFN γ. • decreases the rate of viral replication by inducing cathelicidins and defensins.
Zinc	<ul style="list-style-type: none"> • inhibits RNA-dependent RNA-polymerase and thereby inhibits SARS-CoV-2 replication. • regulates the function and proliferation of neutrophils, macrophages, natural killer cells and lymphocytes and controls the production of cytokines by the immune cells • provides protection against ROS effects of the virus

Anticoagulants

There is a rising concern regarding the occurrence of hypercoagulability in individuals with COVID-19.¹¹² The exact mechanism behind this association is yet to be elucidated. The WHO recommends the prophylactic use of low molecular weight heparin (if available) or unfractionated heparin to reduce the incidence of thromboembolic events in hospitalized adults and adolescents with severe COVID-19.¹¹³ The NIH COVID-19 treatment guidelines recommend prophylaxis for venous thromboembolism in hospitalized adult COVID-19 patients unless contraindicated. In COVID-19 patients who experience a thromboembolic event or in whom there is high suspicion, therapeutic anticoagulation is recommended as per the standard of care followed in non-COVID 19 cases. Patients who are managed on an outpatient basis shouldn't be started on specific drugs for either prophylaxis or at therapeutic doses.¹¹⁴ There is insufficient evidence on the incidence of thromboembolism and the outcomes of different antithrombotic therapies in COVID-19 patients. With the emergence of more data in this regard, we can expect standardized protocols to be in place for the management of hypercoagulability in COVID-19.

Convalescent plasma therapy

Convalescent plasma which is obtained from recovered patients with viral infections has been employed as a final approach to increase the survival rate of various influenza virus affected patients without the appearance of serious adverse events.

The probable therapeutic action of convalescent plasma seems to be through suppression of viremia by the immunoglobulin antibodies present in them.^{115,116}

Shen et al. observed clinical improvement and reduced viral loads in five laboratory-confirmed critically ill COVID-19 hospitalized patients with ARDS in whom convalescent plasma obtained from recovered patients was transfused.¹¹⁷ The USA FDA has approved convalescent plasma therapy for patients with severe COVID-19 infections. The Indian Council of Medical

Research (ICMR) has been conducting trials on convalescent plasma therapy for COVID patients.

Conclusion

As of now, there is no specific recommended treatment for COVID-19 due to insufficient evidence. The management strategy for COVID-19 as suggested by WHO mainly consists of prevention of infection, early case detection and prompt monitoring and adequate supportive care.¹¹⁸ There are antivirals that have been proven to be effective as per currently available data. However, the status of the drugs being tried for this infection is undergoing drastic changes following reports from different parts of the world. Many clinical trials are in progress with the hope to find a suitable treatment option for this fast-spreading ailment. Only time will uncover a solution to overcome this pandemic.

References:

1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA. Severe acute respiratory syndrome-related coronavirus: The species and its viruses—a statement of the Coronavirus Study Group. bioRxiv. 2020; 937862
2. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6. PMID: 32147516; PMCID: PMC7135364
3. WHOcoronavirus(COVID19)dashboard.<https://www.who.int/emergencies/diseases/new-coronavirus-2019>. Accessed 03 August 2020.

4. Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al . Drug targets for corona virus: A systematic review. *Indian J Pharmacol.* 2020;52(1):56-65. doi: 10.4103/ijp.IJP_115_20. Epub 2020 Mar 11. PMID: 32201449; PMCID: PMC7074424.
5. Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Costenbader KH, Ramsey-Goldman R, Lim SS, Esdaile JM, Clarke AE. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. *Arthritis research & therapy.* 2018 Dec;20(1):133.
6. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). *Ophthalmology.* 2016;123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16. PMID: 26992838..
7. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. PMID: 32205204; PMCID: PMC7102549.
8. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7. PMID: 32379955; PMCID: PMC7224609.
9. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis.* 2020;97:396-403. doi: 10.1016/j.ijid.2020.06.099. Epub 2020 Jul 2. PMID: 32623082; PMCID: PMC7330574.
10. Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, et al. Healthcare workers

- & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151(5):459-467. doi: 10.4103/ijmr.IJMR_2234_20. PMID: 32611916.
11. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3. PMID: 32492293; PMCID: PMC7289276.
12. Food and Drug Administration (FDA). FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems (2020) <https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or>
13. Indian Council of Medical Research. Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory dated 23rd March. [https://www.icmr.gov.in/pdf/covid/techdoc/V5 Revised advisory on the use of HC Q SARS CoV2 infection.pdf](https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf). Accessed Aug 30, 2020.
14. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2):e00221-18. doi: 10.1128/mBio.00221-18. PMID: 29511076; PMCID: PMC5844999.
15. Cao B. 2020. Mild/moderate 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov.<https://clinicaltrials.gov/ct2/show/NCT04252664> [Google Scholar]

16. Cao B. 2020. Severe 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov.<https://clinicaltrials.gov/ct2/show/NCT04257656> [Google Scholar]
17. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med.* 2020;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31. PMID: 32004427; PMCID: PMC7092802
18. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. PMID: 32275812; PMCID: PMC7169476.
19. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Chakraborty C. Response to: Status of Remdesivir: Not Yet Beyond Question! *Arch Med Res.* 2020 Sep 15. doi: 10.1016/j.arcmed.2020.09.005. Epub ahead of print. PMCID: PMC7492007.
20. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. *Antiviral Res.* 2013;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29. PMID: 24084488; PMCID: PMC3880838.
21. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. *Pharm Ther.* 2020;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22. PMID: 32097670; PMCID: PMC7102570.
22. Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, et al. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). *Mol Pharmacol.* 2013;84(4):615-29. doi: 10.1124/mol.113.087247. Epub 2013 Aug 1. PMID: 23907213

23. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. *Proc Jpn Acad Ser B Phys Biol Sci.* 2017;93(7):449-463. doi: 10.2183/pjab.93.027. PMID: 28769016; PMCID: PMC5713175.
24. Abdelnabi R, Morais ATS, Leysen P, Imbert I, Beaucourt S, Blanc H, et al. Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. *J Virol.* 2017;91(12):e00487-17. doi: 10.1128/JVI.00487-17. PMID: 28381577; PMCID: PMC5446660.
25. Costanzo M, De Giglio MAR, Roviello GN. SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. *Curr Med Chem.* 2020 Apr16. doi: 10.2174/0929867327666200416131117. Epub ahead of print. PMID: 32297571.
26. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering* (18 March, 2020). <https://doi.org/10.1016/j.eng.2020.03.007>
27. Newsroom Glenmark <https://www.glenmarkpharma.com/media/newsroom>. Accessed 25 Aug 2020
28. Favipiravir | Appili Therapeutics <https://www.appilitherapeutics.com/favipiravir>. Accessed 25 Aug 2020.
29. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. *Curr Opin Infect Dis.* 2019;32(2):176-186. doi: 10.1097/QCO.0000000000000532. PMID: 30724789; PMCID: PMC6416007.

30. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax*. 2004;59(3):252-6. doi: 10.1136/thorax.2003.012658. PMID: 14985565; PMCID: PMC1746980.
31. Phillips KD. Protease inhibitors: a new weapon and a new strategy against HIV. *J Assoc Nurses AIDS Care*. 1996;7(5):57-71. doi: 10.1016/S1055-3290(96)80049-5. PMID: 8906736.
32. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun*. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6. PMID: 31924756; PMCID: PMC6954302.
33. Cheng CY, Lee YL, Chen CP, Lin YC, Liu CE, Liao CH, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. *J Microbiol Immunol Infect*. 2020 ;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3. PMID: 32331982; PMCID: PMC7194913.
34. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18. PMID: 32187464; PMCID: PMC7121492
35. No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients

- studied in RECOVERY — RECOVERY Trial . [https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir](https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patientsstudied-in-recovery) in-hospitalised-covid-19-patientsstudied-in-recovery. Accessed 26 Aug 2020.
36. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. <https://www.who.int/newsroom/detail/04-07-2020-who-discontinueshydroxychloroquine-and-lopinavir-ritonavirtreatment-arms-for-covid-19>. Accessed 27 Aug 2020.
37. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. *Ther Clin Risk Manag.* 2008;4(5):1023-33. doi: 10.2147/tcrm.s3285. PMID: 19209283; PMCID: PMC2621403.
38. Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). *Hum Vaccines Immunother.* 2017;13(9):1972–88.
39. ACTEMRA (tocilizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf. Accessed 16 April 2020.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: *Lancet.* 2020 Jan 30: PMID: 31986264; PMCID: PMC7159299.
41. Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? *J Transl Med.* 2020;18(1):164. doi: 10.1186/s12967-020-02339-3. PMID: 32290839; PMCID: PMC7154566.
42. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a

- 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis.* 2008;67(11):1516-23. doi: 10.1136/ard.2008.092932. Epub 2008 Jul 14. Erratum in: *Ann Rheum Dis.* 2009;68(2):296. PMID: 18625622; PMCID: PMC3811149.
43. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet Rheumatol.* 2020;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24. Erratum in: *Lancet Rheumatol.* 2020 Oct;2(10):e591. PMID: 32835257; PMCID: PMC7314456.
44. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. *EClinicalMedicine.* 2020 Jun 20;24:100418. doi: 10.1016/j.eclinm.2020.100418. PMID: 32766537; PMCID: PMC7305505.
45. Ramiro S, Mostard RLM, Magro-Checa C, van Dongen CMP, Dormans T, Buijs J, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. *Ann Rheum Dis.* 2020;79(9):1143-1151. doi: 10.1136/annrheumdis-2020-218479. Epub 2020 Jul 20. PMID: 32719045; PMCID: PMC7456552.
46. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. "<https://www.roche.com/investors/updates/inv-update-2020-07-29.htm>". Accessed 11 August 2020.
47. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04327388, An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized

- Patients With COVID19; 2020 Mar 26 [cited 2020 August 11]; [about 9 pages]. <https://clinicaltrials.gov/ct2/show/NCT04327388>.
48. Voiriot G, Razazi K, Amsellem V, Tran Van Nhieu J, Abid S, Adnot S, et al. Interleukin-6 displays lung anti-inflammatory properties and exerts protective hemodynamic effects in a double-hit murine acute lung injury. *Respir Res.* 2017 Apr 19;18(1):64. doi: 10.1186/s12931-017-0553-6. PMID: 28424078; PMCID: PMC5397701.
49. McCarty D, Robinson A. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. *Ther Adv Musculoskelet Dis.* 2018;10(3):61-67. doi: 10.1177/1759720X17752037. Epub 2018 Jan 11. PMID: 29492111; PMCID: PMC5802641.
50. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. *Proc Natl Acad Sci U S A.* 2017;114(2):206-214. doi: 10.1073/pnas.1617020114. Epub 2016 Dec 21. PMID: 28003465; PMCID: PMC5240704.
51. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv.* 2020 doi: 10.1101/2020.03.17.20037432.
52. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *J Med Virol.* 2020:10.1002/jmv.26256. doi: 10.1002/jmv.26256. Epub ahead of print. PMID: 32617989; PMCID: PMC7361300.
53. Swedish Orphan Biovitrum AB. Kineret[®] (anakinra) injection, solution prescribing information. Stockholm: Swedish Orphan Biovitrum AB; 2018. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d74915-6606-4570-9c52-c4001d3177de>. Accessed 21 August 2020.

54. Monteagudo LA, Boothby A, Gertner E. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome. *ACR Open Rheumatol.* 2020;2(5):276-282. doi: 10.1002/acr2.11135. Epub 2020 Apr 21. PMID: 32267081; PMCID: PMC7231518.
55. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. *Ann Rheum Dis.* 2020;79(10):1381-1382. doi: 10.1136/annrheumdis-2020-217706. Epub 2020 May 6. PMID: 32376597.
56. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol.* 2020;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7. PMID: 32501454; PMCID: PMC7252085.
57. Hong D, Yang Z, Han S, Liang X, Ma K, Zhang X. Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety. *Drug Des Devel Ther.* 2014;8:2345-57. doi: 10.2147/DDDT.S73428. PMID: 25473268; PMCID: PMC4251663.
58. Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. *Cell Commun Signal.* 2017;15(1):23. doi: 10.1186/s12964-017-0177-y. PMID: 28637459; PMCID: PMC5480189.
59. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30. PMID: 32007145; PMCID: PMC7159086.

60. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet*. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4. Erratum in: *Lancet*. 2020 Jun 20;395(10241):1906. PMID: 32032529; PMCID: PMC7137985.
61. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. *Lancet Infect Dis*. 2020;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. PMID: 32113509; PMCID: PMC7158903.
62. Cantini F, Niccoli L, Matarrese D, Nicastrì E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. *J Infect*. 2020;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23. PMID: 32333918; PMCID: PMC7177073.
63. Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19. *Pharmacotherapy*. 2020;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27. PMID: 32542785; PMCID: PMC7323235.
64. Olumiant, INN-baricitinib. In: ema.europa.eu [database on the internet]. [cited 2020 August 08]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
65. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet*. 2020;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7. PMID: 32043983; PMCID: PMC7134694.
66. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids

- on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. *Eur Respir J*. 1999;14(1):218-20. doi: 10.1034/j.1399-3003.1999.14a37.x. PMID: 10489855.
67. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference. *Neuroimmunomodulation*. 2002-2003;10(5):247-60. doi: 10.1159/000069969. PMID: 12759562.
68. Hylands M, Moller MH, Asfar P, Toma A, Frenette AJ, Beaudoin N, et al. A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension. *Can J Anaesth*. 2017;64(7):703-715. English. doi: 10.1007/s12630-017-0877-1. Epub 2017 May 11. PMID: 28497426.
69. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. Accessed 09 August 2020.
70. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 13 Mar 2020. [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected). Accessed 09 August 2020.
71. Wang Y, Jiang W, He Q, et al Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv. Preprint posted March 12, 2020. doi:[10.1101/2020.03.06.20032342v1](https://doi.org/10.1101/2020.03.06.20032342v1)
72. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute

- Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. PMID: 32167524; PMCID: PMC7070509.
73. Farkas J. Internet Book of Critical Care. <https://emcrit.org/ibcc/COVID19/>. Accessed 08 August 2020.
74. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585. PMID: 32031570; PMCID: PMC7042881.
75. World Health Organization Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected [https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected). Accessed 09 August 2020
76. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet.* 2020;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7. PMID: 32043983; PMCID: PMC7134694.
77. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. *Drug Saf.* 2020;43(8):691-698. doi: 10.1007/s40264-020-00976-7. PMID: 32696429; PMCID: PMC7371963.
78. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. *Clin Microbiol Rev.* 2010;23(3):590-615. doi: 10.1128/CMR.00078-09. PMID: 20610825; PMCID: PMC2901655.

79. Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. *J Antibiot (Tokyo)*. 2019;72(10):759-768. doi: 10.1038/s41429-019-0204-x. Epub 2019 Jul 12. PMID: 31300721.
80. Lin SJ, Kuo ML, Hsiao HS, Lee PT. Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells. *Int Immunopharmacol*. 2016;40:318-326. doi: 10.1016/j.intimp.2016.09.012. Epub 2016 Sep 21. PMID: 27664570.
81. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020;323(24):2493-2502. doi: 10.1001/jama.2020.8630. PMID: 32392282; PMCID: PMC7215635.
82. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. PMID: 32205204; PMCID: PMC7102549.
83. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarne D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect*. 2020;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30. PMID: 32240719; PMCID: PMC7195369.
84. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. *CMAJ*. 2020;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8. Erratum in:

- CMAJ. 2020 May 25;192(21):E590. PMID: 32269021; PMCID: PMC7207200.
85. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3. PMID: 32251768; PMCID: PMC7129059.
86. Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. *Curr Opin Cell Biol.* 2019;58:50-60. doi: 10.1016/j.ceb.2019.01.001. Epub 2019 Feb 28. PMID: 30826604.
87. Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in *Antiviral Research*, widespread interest, an FDA warning, two letters to the editor and the authors' responses. *Antiviral Res.* 2020;178:104805. doi: 10.1016/j.antiviral.2020.104805. Epub 2020 Apr 21. PMID: 32330482; PMCID: PMC7172803.
88. Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. *Clin Pharmacol Ther.* 2020;108(4):762-765. doi: 10.1002/cpt.1889. Epub 2020 Jun 7. PMID: 32378737; PMCID: PMC7267287
89. Sharun K, Shyamkumar TS, Aneesha VA, Dhama K, Pawde AM, Pal A. Current therapeutic applications and pharmacokinetic modulations of ivermectin. *Vet World.* 2019;12(8):1204-1211. doi: 10.14202/vetworld.2019.1204-1211. Epub 2019 Aug 8. PMID: 31641298; PMCID: PMC6755388.
90. Mousavi S, Bereswill S, Heimesaat MM. Immunomodulatory and Antimicrobial Effects of Vitamin C. *Eur J Microbiol Immunol (Bp).* 2019;9(3):73-79. doi: 10.1556/1886.2019.00016. PMID: 31662885; PMCID: PMC6798581.
91. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. *FASEB J.* 1996;10(7):709-20. doi: 10.1096/fasebj.10.7.8635688. PMID: 8635688.
92. Cárcamo JM, Bórquez-Ojeda O, Golde DW. Vitamin C inhibits granulocyte macrophage-

- colony-stimulating factor-induced signaling pathways. *Blood*. 2002;99(9):3205-12. doi: 10.1182/blood.v99.9.3205. PMID: 11964284.
93. Chen Y, Luo G, Yuan J, Wang Y, Yang X, Wang X, et al. Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages. *Mediators Inflamm*. 2014;2014:426740. doi: 10.1155/2014/426740. Epub 2014 Sep 1. PMID: 25253919; PMCID: PMC4165740.
94. Jin X, Su R, Li R, Song L, Chen M, Cheng L, et al. Amelioration of particulate matter-induced oxidative damage by vitamin c and quercetin in human bronchial epithelial cells. *Chemosphere*. 2016;144:459-66. doi: 10.1016/j.chemosphere.2015.09.023. Epub 2015 Sep 18. PMID: 26386771.
95. Furuya A, Uozaki M, Yamasaki H, Arakawa T, Arita M, Koyama AH. Antiviral effects of ascorbic and dehydroascorbic acids in vitro. *Int J Mol Med*. 2008;22(4):541-5. PMID: 18813862.
96. Fowler AA 3rd, Truitt JD, Hite RD, Morris PE, DeWilde C, Priddy A, et al. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. *JAMA*. 2019;322(13):1261-1270. doi: 10.1001/jama.2019.11825. Erratum in: *JAMA*. 2020 Jan 28;323(4):379. PMID: 31573637; PMCID: PMC6777268.
97. Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? *Med Drug Discov*. 2020;5:100028. doi: 10.1016/j.medidd.2020.100028. Epub 2020 Mar 26. PMID: 32328576; PMCID: PMC7167497.
98. Liu F, Zhu Y, Zhang J, Li Y, Peng Z. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. *BMJ*

- Open. 2020;10(7):e039519. doi: 10.1136/bmjopen-2020-039519. PMID: 32641343; PMCID: PMC7348463.
99. Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. *Rev Med Virol.* 2019;29(2):e2032. doi: 10.1002/rmv.2032. Epub 2019 Jan 6. PMID: 30614127.
100. Agier J, Efenberger M, Brzezińska-Błaszczuk E. Cathelicidin impact on inflammatory cells. *Cent Eur J Immunol.* 2015;40(2):225-35. doi: 10.5114/ceji.2015.51359. Epub 2015 Aug 3. PMID: 26557038; PMCID: PMC4637384.
101. Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. *APMIS.* 2019;127(10):681-687. doi: 10.1111/apm.12982. Epub 2019 Jul 26. PMID: 31274211
102. Gombart AF, Pierre A, Maggini S. A Review of Micronutrients and the Immune System-Working in Harmony to Reduce the Risk of Infection. *Nutrients.* 2020;12(1):236. doi: 10.3390/nu12010236. PMID: 31963293; PMCID: PMC7019735.
103. Youssef DA, Ranasinghe T, Grant WB, Peiris AN. Vitamin D's potential to reduce the risk of hospital-acquired infections. *Dermatoendocrinol.* 2012;4(2):167-75. doi: 10.4161/derm.20789. PMID: 22928073; PMCID: PMC3427196.
104. Wimalawansa S.J. Global epidemic of coronavirus--COVID-19: What we can do to minimize risks. *Eur. J. Biomed. Pharm. Sci.* 2020;7:432–438.
105. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. *PLoS One.* 2010;5(6):e11088. doi: 10.1371/journal.pone.0011088. PMID: 20559424; PMCID: PMC2885414.
106. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, Keller F, Cantù

- M. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2. *Nutrients*. 2020;12(5):1359. doi: 10.3390/nu12051359. PMID: 32397511; PMCID: PMC7285131.
107. Kumar A, Kubota Y, Chernov M, Kasuya H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. *Med Hypotheses*. 2020;144:109848. doi: 10.1016/j.mehy.2020.109848. Epub ahead of print. PMID: 32512490; PMCID: PMC7247509.
108. Ibs KH, Rink L. Zinc-altered immune function. *J Nutr*. 2003;133(5 Suppl 1):1452S-6S. doi: 10.1093/jn/133.5.1452S. PMID: 12730441.
109. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010;6(11):e1001176. doi: 10.1371/journal.ppat.1001176. PMID: 21079686; PMCID: PMC2973827.
110. Hasan R, Rink L, Haase H. Chelation of Free Zn²⁺ Impairs Chemotaxis, Phagocytosis, Oxidative Burst, Degranulation, and Cytokine Production by Neutrophil Granulocytes. *Biol Trace Elem Res*. 2016;171(1):79-88. doi: 10.1007/s12011-015-0515-0. Epub 2015 Sep 23. PMID: 26400651.
111. Saper RB, Rash R. Zinc: an essential micronutrient. *Am Fam Physician*. 2009;79(9):768-72. PMID: 20141096; PMCID: PMC2820120.
112. Fei Y, Tang N, Liu H, Cao W. Coagulation dysfunction: A hallmark in COVID-19. *Arch Pathol Lab Med*. 2020. doi: 10.5858/arpa.2020-0324-SA. Epub ahead of print. PMID: 32551814.
113. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance- WHO. Available from:

<https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>. Accessed 3 September 2020.

114. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. <https://www.covid19treatmentguidelines.nih.gov/>. Accessed 3 September 2020.
115. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27. PMID: 32113510; PMCID: PMC7128218.
116. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020;323(16):1582-1589. doi: 10.1001/jama.2020.4783. PMID: 32219428; PMCID: PMC7101507.
117. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance. <https://apps.who.int/iris/handle/10665/331446>. Accessed 30 Jun 2020.
118. Revised guidelines on clinical management of COVID 19. Government of India Ministry of Health & Family Welfare Directorate General of Health Services (EMR Division). <https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf>. Accessed 30 June 2020.